Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1884979
Japan Pharmaceuticals and Healthcare Report Q4 2011
Description:
Business Monitor International's Japan Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Japan's pharmaceuticals and healthcare industry.
BMI View: Japan's pharmaceutical market is a compulsory destination for manufacturers of patented drugs and, increasingly, generic and over-the-counter (OTC) medicines. The regulatory regime has many unique features including the ‘drug lag', the ‘90% rule', a divergent biosimilar approval pathway, biennial price cuts, Iyaku Bungyo and requiring local clinical trials for approval. Japan's ageing population, state support for the provision of healthcare and a large economy are the main attractions for drugmakers.
Headline Expenditure Projections
- Pharmaceuticals: JPY9,525bn (US$109.25bn) in 2010 to JPY9,664bn (US$117.88bn) in 2011; +1.5% in local currency terms and +7.9% in US dollar terms. Our forecast has been revised up from Q311 due to macroeconomic factors and additional analyst intervention.
- Healthcare: JPY39,432bn (US$452.30bn) in 2010 to JPY39,624bn (US$483.21bn) in 2011; +0.5% in local currency terms and -6.8% in US dollar terms. Our forecast has been revised down from Q211 due to macroeconomic factors and additional analyst intervention.
- Medical Devices: JPY2,755bn (US$31.60bn) in 2010 to JPY2,846bn (US$34.71bn) in 2011; +3.3% in local currency terms and +9.8% in US dollar terms. Our forecast has been revised up from Q311 due to macroeconomic factors and additional analyst intervention.
Business Environment Rating: Japan remains the most attractive pharmaceutical market in Asia Pacific, according to BMI's Business Environment Ratings (BERs) for Q411. The country's score of 68.9 out of 100 is unchanged for the previous two quarters. Japan scores highly for all BER sub-sectors, particularly Industry Risks, which comprises Intellectual Property Regime, Approvals Process and Policy/Reimbursement.
Key Trends & Developments
- In July 2011, Teva Pharmaceutical Industries acquired 100% of the outstanding shares of Japan's Taiyo Pharmaceutical Industry for US$934mn in cash. Taiyo is the third largest generic drug manufacturer in Japan, with a portfolio of over 550 products and sales of approximately US$530mn in 2010. Teva will also gain access to Taiyo's strong research and development (R&D) team, local regulatory expertise and a state of the art production facility. Following the acquisition, Teva expects to attain US$1bn in sales in Japan, ahead of its original 2015 target.
- In May 2011, Takeda acquired privately-held Swiss pharmaceutical company Nycomed for US$13.7bn. The cash payment is inclusive of Nycomed's net debt, which stood at EUR3.60bn (US$5.05bn) at the end of 2010, and will be financed in part with a US$7.3-8.5bn loan. The acquisition, expected to be completed by September 2011, does not include Nycomed's US dermatology business, which Takeda said did not offer synergies with its own operations.
BMI Economic View: Real GDP contracted by 0.9% quarter-on-quarter (q-o-q) in Q111, sending the Japanese economy back into recession. While the March earthquake and tsunami were partially to blame, the country's underlying economic weakness was evident in the data, suggesting that there will be no swift recovery once the crisis passes. BMI sees real GDP growth coming in at 0.7% in 2011 and 1.8% in 2012, compared with consensus expectations of 1.3% and 2.0% respectively, and note that the risks to both of these are weighted to the downside.
BMI Political View: Prime Minister Naoto Kan is facing increasing pressure from lawmakers to step down, a move believed to come in August 2011. Indeed, the recent resignation of Reconstruction Minister Ryu Matsumoto a week after his appointment further reinforces our view. The Japanese political scene is expected to remain chaotic over the coming years, although a grand coalition should provide some stability until the end of the current parliamentary term in 2013.
BMI View: Japan's pharmaceutical market is a compulsory destination for manufacturers of patented drugs and, increasingly, generic and over-the-counter (OTC) medicines. The regulatory regime has many unique features including the ‘drug lag', the ‘90% rule', a divergent biosimilar approval pathway, biennial price cuts, Iyaku Bungyo and requiring local clinical trials for approval. Japan's ageing population, state support for the provision of healthcare and a large economy are the main attractions for drugmakers.
Headline Expenditure Projections
- Pharmaceuticals: JPY9,525bn (US$109.25bn) in 2010 to JPY9,664bn (US$117.88bn) in 2011; +1.5% in local currency terms and +7.9% in US dollar terms. Our forecast has been revised up from Q311 due to macroeconomic factors and additional analyst intervention.
- Healthcare: JPY39,432bn (US$452.30bn) in 2010 to JPY39,624bn (US$483.21bn) in 2011; +0.5% in local currency terms and -6.8% in US dollar terms. Our forecast has been revised down from Q211 due to macroeconomic factors and additional analyst intervention.
- Medical Devices: JPY2,755bn (US$31.60bn) in 2010 to JPY2,846bn (US$34.71bn) in 2011; +3.3% in local currency terms and +9.8% in US dollar terms. Our forecast has been revised up from Q311 due to macroeconomic factors and additional analyst intervention.
Business Environment Rating: Japan remains the most attractive pharmaceutical market in Asia Pacific, according to BMI's Business Environment Ratings (BERs) for Q411. The country's score of 68.9 out of 100 is unchanged for the previous two quarters. Japan scores highly for all BER sub-sectors, particularly Industry Risks, which comprises Intellectual Property Regime, Approvals Process and Policy/Reimbursement.
Key Trends & Developments
- In July 2011, Teva Pharmaceutical Industries acquired 100% of the outstanding shares of Japan's Taiyo Pharmaceutical Industry for US$934mn in cash. Taiyo is the third largest generic drug manufacturer in Japan, with a portfolio of over 550 products and sales of approximately US$530mn in 2010. Teva will also gain access to Taiyo's strong research and development (R&D) team, local regulatory expertise and a state of the art production facility. Following the acquisition, Teva expects to attain US$1bn in sales in Japan, ahead of its original 2015 target.
- In May 2011, Takeda acquired privately-held Swiss pharmaceutical company Nycomed for US$13.7bn. The cash payment is inclusive of Nycomed's net debt, which stood at EUR3.60bn (US$5.05bn) at the end of 2010, and will be financed in part with a US$7.3-8.5bn loan. The acquisition, expected to be completed by September 2011, does not include Nycomed's US dermatology business, which Takeda said did not offer synergies with its own operations.
BMI Economic View: Real GDP contracted by 0.9% quarter-on-quarter (q-o-q) in Q111, sending the Japanese economy back into recession. While the March earthquake and tsunami were partially to blame, the country's underlying economic weakness was evident in the data, suggesting that there will be no swift recovery once the crisis passes. BMI sees real GDP growth coming in at 0.7% in 2011 and 1.8% in 2012, compared with consensus expectations of 1.3% and 2.0% respectively, and note that the risks to both of these are weighted to the downside.
BMI Political View: Prime Minister Naoto Kan is facing increasing pressure from lawmakers to step down, a move believed to come in August 2011. Indeed, the recent resignation of Reconstruction Minister Ryu Matsumoto a week after his appointment further reinforces our view. The Japanese political scene is expected to remain chaotic over the coming years, although a grand coalition should provide some stability until the end of the current parliamentary term in 2013.
Contents:
Executive Summary
SWOT Analysis
Japan Pharmaceuticals And Healthcare Industry SWOT
Japan Political SWOT
Japan Economic SWOT
Japan Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Asia Pacific – Regional Pharmaceutical Business Environment Ratings, Q411
Rewards
Risks
Japan – Market Summary
Regulatory Regime
Recent Regulatory Developments
Intellectual Property Developments
Pricing and Reimbursement System
Table: Reimbursement Categories And Rates Recent Pricing and Reimbursement Developments
Other Regulatory Issues
Table: Concerns Of Pharmaceutical Associations
Industry Trends and Developments
Epidemiology
Non-Communicable Diseases
Communicable Diseases
Mental Health
Healthcare Sector
Healthcare Sector Financing
Healthcare Reforms
International Reaction
Medical Tourism
Research and Development
Clinical Trials
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Table: Japan's Pharmaceutical Market Forecast, 2008-2015
Key Growth Factors – Industry
Table: Japan's Healthcare Expenditure Forecast, 2008-2015
Macroeconomic Outlook
Table: Japan – Economic Activity, 2008-2015
Prescription Drug Market Forecast
Table: Japan's Prescription Drug Market Forecast, 2008-2015
Patented Drug Market Forecast
Table: Japan's Patented Drug Market Forecast, 2008-2015
Generic Drug Market Forecast
Japan Pharmaceuticals and Healthcare Report Q4 2011
Table: Japan's Patented Drug Market Forecast, 2008-2015
OTC Medicine Market Forecast
Table: Japan's OTC Medicine Market Forecast, 2008-2015
Table: Japan's OTC Medicine Market Forecast, 2004-2009
Medical Device Market Forecast
Table: Japan's Medical Device Market Forecast, 2008-2015
Pharmaceutical Trade Forecast
Table: Japan's Medical Device Market Forecast, 2008-2015
Other Healthcare Data
Key Risks to BMI's Forecast Scenario
Competitive Landscape
Pharmaceutical Industry
Top 20 Pharmaceutical Companies According To Market Capitalisation On The Tokyo Stock Exchange
Foreign Generic Drug Sector
Pharmaceutical Wholesale and Retail
Company Profiles
Leading Local Manufacturers
Takeda Pharmaceutical Company
Astellas
Eisai
Daiichi Sankyo
Mitsubishi Tanabe
Sawai Pharmaceutical
Leading Foreign Manufacturers
Pfizer
Sanofi-Aventis
Merck & Co (Banyu
Novartis
GlaxoSmithKline (GSK)
AstraZeneca
Country Snapshot: Japan Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012
Glossary
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting Table: Weighting Of Components
Sources
SWOT Analysis
Japan Pharmaceuticals And Healthcare Industry SWOT
Japan Political SWOT
Japan Economic SWOT
Japan Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Asia Pacific – Regional Pharmaceutical Business Environment Ratings, Q411
Rewards
Risks
Japan – Market Summary
Regulatory Regime
Recent Regulatory Developments
Intellectual Property Developments
Pricing and Reimbursement System
Table: Reimbursement Categories And Rates Recent Pricing and Reimbursement Developments
Other Regulatory Issues
Table: Concerns Of Pharmaceutical Associations
Industry Trends and Developments
Epidemiology
Non-Communicable Diseases
Communicable Diseases
Mental Health
Healthcare Sector
Healthcare Sector Financing
Healthcare Reforms
International Reaction
Medical Tourism
Research and Development
Clinical Trials
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Table: Japan's Pharmaceutical Market Forecast, 2008-2015
Key Growth Factors – Industry
Table: Japan's Healthcare Expenditure Forecast, 2008-2015
Macroeconomic Outlook
Table: Japan – Economic Activity, 2008-2015
Prescription Drug Market Forecast
Table: Japan's Prescription Drug Market Forecast, 2008-2015
Patented Drug Market Forecast
Table: Japan's Patented Drug Market Forecast, 2008-2015
Generic Drug Market Forecast
Japan Pharmaceuticals and Healthcare Report Q4 2011
Table: Japan's Patented Drug Market Forecast, 2008-2015
OTC Medicine Market Forecast
Table: Japan's OTC Medicine Market Forecast, 2008-2015
Table: Japan's OTC Medicine Market Forecast, 2004-2009
Medical Device Market Forecast
Table: Japan's Medical Device Market Forecast, 2008-2015
Pharmaceutical Trade Forecast
Table: Japan's Medical Device Market Forecast, 2008-2015
Other Healthcare Data
Key Risks to BMI's Forecast Scenario
Competitive Landscape
Pharmaceutical Industry
Top 20 Pharmaceutical Companies According To Market Capitalisation On The Tokyo Stock Exchange
Foreign Generic Drug Sector
Pharmaceutical Wholesale and Retail
Company Profiles
Leading Local Manufacturers
Takeda Pharmaceutical Company
Astellas
Eisai
Daiichi Sankyo
Mitsubishi Tanabe
Sawai Pharmaceutical
Leading Foreign Manufacturers
Pfizer
Sanofi-Aventis
Merck & Co (Banyu
Novartis
GlaxoSmithKline (GSK)
AstraZeneca
Country Snapshot: Japan Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012
Glossary
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting Table: Weighting Of Components
Sources
Companies Mentioned
- Astellas
- Eisai
- Daiichi Sankyo
- Mitsubishi Tanabe
- Sawai Pharmaceutical
- Leading Foreign Manufacturers
- Pfizer
- Sanofi-Aventis
- Merck & Co (Banyu)
- Novartis
- GlaxoSmithKline (GSK)
- AstraZeneca
- Eisai
- Daiichi Sankyo
- Mitsubishi Tanabe
- Sawai Pharmaceutical
- Leading Foreign Manufacturers
- Pfizer
- Sanofi-Aventis
- Merck & Co (Banyu)
- Novartis
- GlaxoSmithKline (GSK)
- AstraZeneca
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Thursday, May 23, 2013
12:35:40 AM
12:35:40 AM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Japan Pharmaceuticals and Healthcare Report Q4 2011
Web Address
http://www.researchandmarkets.com/reports/1884979
Office Code
OC8DIQSOSPOQUV
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Electronic (PDF) - Single User |
|
EURO€ 874.00 |
|---|
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Thursday, May 23, 2013
12:35:40 AM
12:35:40 AM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp